Free Trial
→ Iran tensions are moving oil, gold, and defense stocks now (From Stock Alert Daily) (Ad)tc pixel Free BLAC Stock Alerts

Bellevue Life Sciences Acquisition (BLAC) Competitors

Bellevue Life Sciences Acquisition logo
$0.58 -0.06 (-8.80%)
As of 05/4/2026
Compare

BLAC vs. SINT, TNON, PAVM, BTCY, and NXL

Should you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Sintx Technologies (SINT), Tenon Medical (TNON), PAVmed (PAVM), Biotricity (BTCY), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.

How does Bellevue Life Sciences Acquisition compare to Sintx Technologies?

Sintx Technologies (NASDAQ:SINT) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Sintx Technologies' average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score.

Company Overall Sentiment
Sintx Technologies Neutral
Bellevue Life Sciences Acquisition Neutral

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sintx Technologies currently has a consensus price target of $11.00, indicating a potential upside of 354.55%. Given Sintx Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Sintx Technologies is more favorable than Bellevue Life Sciences Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,018.08%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Sintx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sintx Technologies-1,018.08% -242.76% -99.86%
Bellevue Life Sciences Acquisition N/A N/A N/A

Sintx Technologies has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500.

Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Sintx Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sintx Technologies$1.02M9.77-$10.36M-$5.66N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

Summary

Sintx Technologies and Bellevue Life Sciences Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to Tenon Medical?

Tenon Medical (NASDAQ:TNON) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Tenon Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenon Medical$3.94M2.13-$12.56M-$1.99N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

In the previous week, Tenon Medical had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for Tenon Medical and 0 mentions for Bellevue Life Sciences Acquisition. Tenon Medical's average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score.

Company Overall Sentiment
Tenon Medical Neutral
Bellevue Life Sciences Acquisition Neutral

Tenon Medical has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Tenon Medical's net margin of -318.36%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Tenon Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Tenon Medical-318.36% -409.16% -110.06%
Bellevue Life Sciences Acquisition N/A N/A N/A

22.7% of Tenon Medical shares are owned by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. 0.3% of Tenon Medical shares are owned by insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenon Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Tenon Medical and Bellevue Life Sciences Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

PAVmed has higher revenue and earnings than Bellevue Life Sciences Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PAVmed$70K115.00$400K-$22.77N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

In the previous week, PAVmed had 3 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 3 mentions for PAVmed and 0 mentions for Bellevue Life Sciences Acquisition. PAVmed's average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score.

Company Overall Sentiment
PAVmed Neutral
Bellevue Life Sciences Acquisition Neutral

PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.

PAVmed has a net margin of 564.79% compared to Bellevue Life Sciences Acquisition's net margin of 0.00%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat PAVmed's return on equity.

Company Net Margins Return on Equity Return on Assets
PAVmed564.79% -242.99% -17.25%
Bellevue Life Sciences Acquisition N/A N/A N/A

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. 5.8% of PAVmed shares are owned by insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PAVmed currently has a consensus price target of $65.00, indicating a potential upside of 707.45%. Given PAVmed's stronger consensus rating and higher probable upside, equities analysts plainly believe PAVmed is more favorable than Bellevue Life Sciences Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

PAVmed beats Bellevue Life Sciences Acquisition on 7 of the 11 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

3.9% of Biotricity shares are held by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 10.1% of Biotricity shares are held by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Biotricity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biotricity$12.06M0.63-$14.09M-$0.16N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

In the previous week, Biotricity's average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score.

Company Overall Sentiment
Biotricity Neutral
Bellevue Life Sciences Acquisition Neutral

Biotricity has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Biotricity's net margin of -80.42%.

Company Net Margins Return on Equity Return on Assets
Biotricity-80.42% N/A -188.47%
Bellevue Life Sciences Acquisition N/A N/A N/A

Summary

Bellevue Life Sciences Acquisition beats Biotricity on 4 of the 6 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to Nexalin Technology?

Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nexalin Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Nexalin Technology's average media sentiment score of 0.31 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Bellevue Life Sciences Acquisition Neutral
Nexalin Technology Neutral

55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bellevue Life Sciences Acquisition has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.

Bellevue Life Sciences Acquisition has higher earnings, but lower revenue than Nexalin Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A
Nexalin Technology$300K24.70-$8.22M-$0.51N/A

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Nexalin Technology's net margin of -2,722.19%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Bellevue Life Sciences AcquisitionN/A N/A N/A
Nexalin Technology -2,722.19%-195.69%-171.05%

Summary

Bellevue Life Sciences Acquisition beats Nexalin Technology on 5 of the 9 factors compared between the two stocks.

Get Bellevue Life Sciences Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLAC vs. The Competition

Export
MetricBellevue Life Sciences AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ Exchange
Market Cap$2.35M$234.51M$4.22B$11.77B
Dividend YieldN/A3.76%5.87%5.26%
P/E RatioN/A2.2723.3727.07
Price / SalesN/A0.14155.5373.43
Price / CashN/A123.3052.0853.90
Price / BookN/A26.6637.876.69
Net IncomeN/A-$8.98M$114.66M$332.64M
7 Day Performance-19.78%0.15%1.21%2.01%
1 Month Performance5.62%48.07%5.50%9.19%
1 Year Performance-58.82%10.37%18.68%39.59%

Bellevue Life Sciences Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLAC
Bellevue Life Sciences Acquisition
N/A$0.58
-8.8%		N/AN/A$2.35MN/AN/AN/A
SINT
Sintx Technologies
3.307 of 5 stars		$2.41
+14.2%		$11.00
+356.4%		N/A$8.70M$1.02MN/A40
TNON
Tenon Medical
0.0589 of 5 stars		$0.78
+2.4%		N/AN/A$8.63M$3.94MN/A8
PAVM
PAVmed
2.1498 of 5 stars		$8.53
+2.8%		$65.00
+662.0%		N/A$8.26M$71KN/A90
BTCY
Biotricity
N/A$0.26
+11.8%		N/AN/A$7.52M$12.06MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BLAC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel